



Published in final edited form as:

Fertil Steril. 2013 February ; 99(2): 318–326. doi:10.1016/j.fertnstert.2012.12.015.

Cardiometabolic health of children conceived by assisted reproductive technologies

Edwina H. Yeung, Ph.D.^a and Charlotte Druschel, M.D., M.P.H.^{b,c}

^a Epidemiology Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland

^b Bureau of Environmental and Occupational Epidemiology, Center for Environmental Health, New York State Department of Health, Albany, New York ^c Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, State University of New York, Rensselaer, New York

Abstract

The cardiometabolic health of children conceived by assisted reproductive technologies (ART) compared with children conceived without medical assistance is unclear. Although the majority of published studies evaluating height, weight, and body mass index have not found differences by method of conception, some studies have indicated differences in adiposity by more direct measures such as skinfolds and dual X-ray absorptiometry. Far fewer studies have investigated other cardiometabolic characteristics, such as blood pressure and measures of lipid and glucose metabolism. Of these studies, some indications of increased blood pressure and recent findings of vascular dysfunction among children conceived by ART compared with children conceived without ART warrant further investigation. Epigenetic differences may be the global mechanism at work, resulting from different aspects of ART treatment, such as ovarian stimulation, in vitro culture, and manipulation of sperm, among other considerations. Fetal growth and placental development may serve as mediators of these effects. Future studies should consider recruiting sufficient numbers of ART and non-ART conceived multiples and collect information on indicators of cardiometabolic health in the parents. Despite some advantages of sibling cohorts in developmental origins research, its feasibility and utility for investigating health of children conceived by ART remains debatable.

Copyright ©2013 American Society for Reproductive Medicine, Published by Elsevier Inc.

Reprint requests: Edwina H. Yeung, Ph.D., *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, Division of Epidemiology, Statistics, and Prevention Research, Epidemiology Branch, 6100 Executive Blvd., 7B03, Bethesda, Maryland 20892 (yeungedw@mail.nih.gov)..

E.H.Y. has nothing to disclose. C.D. receives grants from the Centers for Disease Control and Prevention and has contracts with the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development that support travel to meetings.



Use your smartphone to scan this QR code and connect to the discussion forum for this article now.*

* Download a free QR code scanner by searching for "QR scanner" in your smartphone's app store or app marketplace.

Discuss: You can discuss this article with its authors and with other ASRM members at <http://fertstertforum.com/yeunge-cardiometabolic-risk-art/>

Keywords

Cardiometabolic risk; assisted reproductive technology; in vitro fertilization; intracytoplasmic sperm injection; children; growth; adiposity; glucose; blood pressure

Assisted reproductive technologies (ART) have aided millions of couples worldwide to have children. In 2009, approximately 1.4% of births in the United States were conceived with ART, an increase from the 2006 estimate of 1.0% of all US births (1, 2). With continued ART success and utilization, any long-term health risks due to ART treatment have the potential to affect a substantial proportion of the population and increase the future health care burden.

Prospective epidemiologic studies have documented associations between birth outcomes and future cardiometabolic health in offspring (3). Such outcomes include low birth weight (<2,500 g) and preterm birth (<37 weeks' gestation), both of which are well documented to be increased in ART singletons and twins (4–6). According to the developmental origins of health and disease hypothesis, these birth outcomes are indicators of non-ideal in utero conditions leading to compensatory fetal development that later increases risk of a host of diseases, including type 2 diabetes mellitus and cardiovascular disease (CVD) (7–9). Therefore, the increased risk of poor birth outcomes among neonates conceived by ART compared with others could be an indicator of greater future cardiometabolic risk.

The goal of this review is to evaluate the evidence to date on the cardiometabolic health of children conceived by ART, to identify important gaps that remain for consideration in future studies. To do so, this review will summarize the evidence to date, discuss some possible biological mechanisms, and comment on the design of future studies. Articles for review were identified through searches conducted on MEDLINE, Scopus, and hand searches of previous reviews (10–13). Case series or other studies lacking an internal comparison group (14–18) or not published in English were excluded. Studies included in this review collected information on cardiometabolic outcomes of growth (height, weight), adiposity, metabolism (glucose, lipids, adipokines, cytokines), and cardiovascular risk (blood pressure, vascular function). Assisted reproductive technologies are defined here as all techniques whereby both eggs and sperm are handled, therefore excluding studies of children conceived solely by, for example, IUI and ovulation induction (OI). However, non-ART comparison groups could consist of children conceived by other treatment methods apart from ART (e.g., OI) or children conceived without any specified medical assistance.

POSTNATAL GROWTH AND ADIPOSITY OF CHILDREN CONCEIVED BY ART

Seventeen studies regarding the growth of children conceived by ART ranging in age from 1 to 18 years were identified, with the majority observing no significant differences in height, weight, or body mass index (BMI) (19–35). Despite a large number of studies, differences in study methodology should be considered for remaining data gaps. Supplemental Tables 1 and 2 (available online) provide information regarding study design, methods, and results of these studies. None of the previous studies were conducted in the United States, even though treatment techniques and population characteristics may differ from the countries captured (36). Ten publications reported observations of children made at age 5 years or younger, but less evidence has been gathered regarding later growth and particularly pubertal growth. Related to the age of the children, studies with information on older children followed those conceived in the 1980s. Metabolic differences observed in the older ART children examined

thus far could be related to the technologies used during that period and may be no longer relevant for more recent cohorts.

Moreover, all but one study (31) of children older than 5 years restricted recruitment to singletons. Of the studies at younger age, the evidence for growth among ART twins/multiples remains inconclusive. Saunders et al. (34) expressed difficulty in recruiting non-ART children, especially matching on multiples, such that they had to exclude triplets and the twin sample size ended up imbalanced (91 IVF vs. 34 non-IVF twins), affecting statistical efficiency to test for differences. Kai et al. (26) included twins, but by 36 months of follow-up only 46 intracytoplasmic sperm injection (ICSI), 30 IVF, and 36 non-ART twins remained. Last, analyses presented were not always clear as to how twins were being counted in the studies. Kai et al. (26) indicated the twins were counted as individuals, but the methods used (e.g., analysis of variance) do not appropriately account for the correlation expected between twin observations with appropriate statistical methods (37). The evidence remains unclear, therefore, whether ART multiples grow differently from non-ART multiples.

Most studies recruited children from a limited number of infertility clinics over a certain time period, along with a comparison group commonly matched on different sociodemographic factors (Supplemental Table 1). In terms of the ART conception group, all studies except for one (28) included children conceived by IVF with or without ICSI, rather than other less frequently used ART techniques (e.g., zygote intrafallopian transfer [ZIFT], gamete intrafallopian transfer [GIFT]). However, the exception, the Taiwan Birth Cohort Study, which included ZIFT/GIFT (28), also included OI in their definition of ART without indicating the number of children conceived by OI (of the 366 total), even though it could be more common than ART. Conversely, Brandes et al. (24) included children conceived by OI in the non-IVF comparison group (32 of 116 non-IVF children). Last, Ceelen et al. (25, 38) recruited a comparison group of only children conceived by subfertile women who experienced unsuccessful conception after 1 year of unprotected intercourse but ultimately conceived without assistance.

As previously discussed by Buck Louis et al. (39), the choice of comparison group affects the interpretation of findings. For Ceelen et al., their comparisons aim to test for an IVF effect on growth among infertile couples. Whether children conceived by subfertile couples are the best comparison group to tease apart the effects of underlying infertility (if such exists) from treatment effects is debatable because couples conceiving after resolved infertility likely do not share the same risk profiles as couples who conceive by ART (39). They are also different from those who choose to utilize other infertility treatments, including medications for OI with or without IUI. That there is a causal effect of underlying infertility on long-term growth and cardiometabolic risk of children remains unproven, but some evidence has arisen that children conceived by couples who are subfertile (with time to pregnancy >2 years) had similar risks of adverse birth outcomes compared with ART-conceived children (40). For the studies by Lee (28) and by Brandes (24), the effect being tested is unclear owing to inclusion of the OI group. For the rest of the studies that did not report information on fecundity, it is assumed that the comparisons made tested for the combined effects of infecundity and treatment (39). Therefore, studies should not restrict inclusion of only children conceived by IVF/ICSI but should more comprehensively recruit those conceived by any infertility treatment while collecting information on underlying infertility (i.e., time to pregnancy).

Moreover, rather than recruiting comparison groups of children conceived by subfertile couples who ultimately resolve their infertility, considerations should be made in collecting and controlling for specific upstream factors that are demonstrated to be causes of infertility

and causes of the child health outcomes in question. For example, obesity is heritable (41), and both maternal and paternal obesity are positively associated with subfertility (42–44). Many studies lacked information on parental BMI or used *t* tests for mean comparisons, which does not allow for adjustment for parental characteristics (Supplemental Table 2). Of the studies that accounted for parental or at least maternal anthropometry (21, 22, 25, 30, 31), results were in conflict but the studies differed in many aspects, including the age of the children.

Because children conceived by ART are at increased risk of preterm birth and low birth weight, the trajectory of growth, especially early catch-up growth, may be a better marker of abnormal growth and marker of long-term cardiometabolic health (45, 46) than cross-sectional comparisons of weight and height. Although studies of ART children had prospective longitudinal measures, some reports were made only of cross-sectional differences at one time point or multiple cross-sectional comparisons at different time points, without further analyses in changes in anthropometry between time points or use of longitudinal methods accounting for correlated repeated data (20, 21, 27). Kai et al. (26) plotted growth charts by conception method, concluding no differences, but ultimately reported *P* values from statistical tests made by cross-sectional comparisons at different time points. Ceelen et al. (38) captured growth data from periodic health examinations reported via postnatal growth charts. Children conceived by IVF had an average of 16 measurements from 0 to 4 years, whereas non-ART children of subfertile couples averaged 14 measurements. Growth velocity, as assessed by gain in weight, height, and BMI during late infancy (i.e., 3 months to 1 year), was significantly higher for the IVF group compared with the non-IVF group, suggesting catch-up growth achieved at that time period. These findings suggest that IVF children follow a similar pattern of growth acceleration early in life as observed in other cohorts of growth-restricted children (38). Growth trajectory by weight or height also did not seem to differ between 1 and 3 years by conception method (38). Those findings are corroborated in another study finding no differences in trajectory by conception methods at older childhood age, capturing data from 0, 5, 7–9, and 10–12 years (19).

Despite no dramatic differences in height, weight, or BMI, some studies measuring body fat more directly have suggested that increases in adiposity cannot be ruled out. Ceelen et al. (25) observed increased peripheral body fat by skinfolds (21.9 vs. 19.7 cm) without differences in BMI among children conceived by IVF vs. children conceived without infertility treatment by parents with resolved infertility. Significantly increased peripheral fat (7.59 vs. 6.69 kg) by dual energy x-ray absorptiometry was also observed in a subgroup of 100 children, comparing the IVF and non-IVF children from the same study who had reached puberty according to Tanner staging (25). Another study that measured adiposity by skinfolds found that girls conceived by ICSI had increased peripheral adiposity (by skinfolds +2.8 mm) and central adiposity (by skinfolds +3.1 mm, waist circumference +2.1 cm, BMI 1.1 kg/m²) compared with non-ART girls (21). For boys, adjusted differences were significant only at advanced pubertal stage (3 or 4 and not 1 or 2), with a 3.5-mm increase in sum of peripheral skinfolds among the IVF compared with the non-IVF group (21). On the other hand, Miles et al. (31) found no differences in percent body fat measured by dual energy x-ray absorptiometry, despite finding lower BMI among prepubertal term children conceived by IVF compared with non-IVF children. Because these studies differ in many aspects of design (Supplemental Table 1), evaluation of adiposity in ART children requires replication.

In summary, despite the large number of studies previously published on weight, height, and/or BMI of children conceived by IVF/ICSI, data remain scarce in some areas, including [1] among children conceived in countries not previously captured, [2] among twins/multiples, [3] sufficient adjustment for shared upstream factors of infertility and childhood

growth/adiposity, [4] longitudinal analyses capturing height and weight trajectories over time, and [5] direct measures of adiposity rather than BMI alone. Future studies capturing information in these areas could help to complete the picture regarding growth and adiposity of children conceived by ART.

METABOLISM

Table 1 captures the handful of studies that have measured some traditional cardiometabolic measures among children conceived by ART compared to non-ART children. Similar to the studies reviewed above, these studies have limitations and are not comparable in study design and methods. Glucose metabolism among children of ART has been of interest. Hyperglycemia, or elevated glucose levels, causes microvascular damage and other sequela. Fasting plasma glucose, insulin, and their derived levels of insulin resistance have been compared between children conceived by ART and other children (31, 48–50). Three of the four studies found no differences in glucose levels, whereas the study by Ceelen et al. (48) found significantly increased levels (+0.2 mmol/L) among pubertal children conceived by IVF compared with children of subfertile parents (Table 1). In addition to investigating older children and comparing children of subfertile couples, the study also had a long recruitment period (1980–1994), which could be a weakness because the older children in the cohort may have been conceived under different ART protocols than the younger children. It also may explain why the other more recent cohorts found no differences. None of the studies found differences in fasting insulin levels. Measures of insulin resistance derived using fasting glucose and insulin by the homeostasis model also did not significantly differ. Taken together, these findings do not provide strong evidence for dysregulation of glucose metabolism among children conceived by ART.

Findings for fasting lipid values were also conflicting among three studies, with children conceived by IVF being observed to have a better lipid profile in one study, contrary to findings of higher triglyceride levels in another study and a third study finding no differences (31, 49, 50) (Table 1). Again, these three studies included very different populations of IVF and non-IVF children. Sakka et al. (49) included multiples, whereas Miles et al. (31) and Scherrer et al. (50) limited findings to term singletons with normal birth weight for the most part. Miles et al. studied a prepubertal group of children, whereas both Sakka et al. and Scherrer et al. had a mix of children at different stages of puberty. Fasting lipid levels have been shown to decrease during puberty, such that the National Heart, Lung, and Blood Institute recommends screening only before and after puberty (51), which may explain the discrepancies in results. As such, the evidence remains equivocal regarding lipid metabolism among ART children.

As for other biomarkers of metabolism, Sakka et al. (49) measured the adipokines adiponectin and leptin and inflammatory markers such as C-reactive protein and interleukin-6, also finding no differences in measured values by infertility treatment exposure. Because of this scant epidemiologic evidence, it is unclear whether these metabolic pathways are indeed associated with ART treatment exposure.

CARDIOVASCULAR RISK

Childhood hypertension has become a critical health concern, with indications that general population mean childhood blood pressure levels have been on the rise, especially among children in the younger age range (8–12 years) (52). Blood pressure tracks from childhood to adulthood (53). The Bogalusa Heart Study (53) has shown that both systolic (SBP) and diastolic (DBP) blood pressure were already significantly elevated during childhood (4–11 years) among individuals who later developed hypertension in adulthood compared with those who did not (54). Long-term consequences of high blood pressure include accelerated

atherosclerosis and end organ damage, including increased risk of myocardial infarction, stroke, renal failure, and retinal damage. Moreover, childhood hypertension has been found to be associated with increased risk of premature death (occurring before 55 years) from endogenous causes among 4,857 American Indian individuals free of diabetes (relative risk 1.57; 95% confidence interval 1.10–2.24) (55). On a population level, even small shifts (2–5 mm Hg) in the distribution of adult blood pressure for a large proportion of individuals can translate into significant mortality (56).

Some evidence has recently emerged calling into question the vascular health of children conceived by ART (57). In an animal study, Watkins et al. (58) found that mice conceived by in vitro culture as well as mice conceived by ovulation stimulation alone had increased SBP later in life compared with naturally conceived mice, even after accounting for litter size (58). Sexual dimorphic results were found in this study as well, with elevated serum angiotensin-converting enzyme demonstrated in female but not the male mice, despite similar blood pressure elevations (58).

Three epidemiologic studies (20, 48, 49) have provided suggestive evidence for increased blood pressure among children conceived by IVF/ICSI, whereas two have not shown a difference (50, 59) (Table 1). Of the two studies that did not find a difference, one was conducted among a similar cohort of children conceived by ICSI that had earlier found a difference at age 8 years (20) but not again at age 14 years (59). The investigators suspect that pubertal influences on blood pressure and the necessity in stratifying results by gender, as well as other differences in measurement methods, may have contributed to the difference in findings for the younger and older ages (59). However, this study was also limited in its cross-sectional design.

In contrast, the study by Scherrer et al. (50), which found no differences in resting SBP or DBP among a small group of children conceived by IVF/ICSI (Table 1), nevertheless found differences in vascular function through more involved testing. Investigators recruited 65 healthy Swiss children conceived by ART (21 IVF, 44 ICSI) and 57 non-ART children recruited by the families of the ART children (including five sibling pairs). All children conceived by ART were singletons born at term without perinatal complications. At assessment, mean age, gestational age, birth weight, BMI, and presence of maternal CVD risk factor did not differ between the two groups. Investigators found significantly faster carotid–femoral pulse-wave velocity (indicating increased arterial stiffness), smaller flow-mediated dilation (FMD) of the brachial artery, and increased carotid intima–media thickness. These measures of atherosclerosis have been shown to correspond to increased risks of heart attacks and strokes in adults (60–62). To account for inherited differences due to parental vascular dysfunction, Scherrer et al. also measured FMD in a subgroup of the parents and found it to not differ by fertility status, although the number of participants was small ($n < 25$ each). The suggestive evidence from this recent study and previous studies of blood pressure elevations calls into question whether vascular differences of children conceived by ART may be of concern, but the evidence can be greatly strengthened by longer follow-up and larger sample sizes, including children of subfertile couples (57).

BIOLOGICAL RATIONALE

Epigenetics as the Global Mechanism

Epigenetic differences have been hypothesized to be the global mechanism behind the health differences found in children conceived by ART (57, 63). The most commonly studied epigenetic mechanism has been DNA methylation, which plays a role in regulating gene transcription through the attachment of a methyl group to cytosine of DNA. A higher number of children conceived by ART in case series studies of children with rare imprinting

disorders (such as Angelman syndrome and Beckwith-Wiedemann syndrome) first alerted the scientific community as to the possibility of DNA methylation differences (64, 65). Imprinting refers to the turning on and off of one copy of inherited genetic material by DNA methylation of either the paternal or maternal gene. In humans, the timing of the establishment of these imprinting marks remains unclear, leaving the possibility that defects can occur at multiple stages of ART, including during times of imprinting establishment in gametes and imprinting maintenance in the embryo (65). The association between ART and imprinting disorders has not been replicated in larger cohorts, including a study capturing all singleton births in Denmark from 1995 to 2001, which observed no imprinting diseases among 6,052 children conceived by IVF according to registry data (66). However, syndromes like Beckwith-Wiedemann syndrome remain very rare (1 in 12,000) (67), which suggests that this previous study could be underpowered. Underreporting could have also played a role because no cases of Beckwith-Wiedemann syndrome were identified even among the >440,000 children conceived without ART, and Angelman Syndrome was not an available diagnosis code (66).

Several DNA methylation studies targeting imprinted genes (e.g., *H19/IGF2*, *SNPRN*, *KCNQ10T1*) using cord blood lymphocyte or placental tissue specimens have not confirmed any global imprinting differences among children conceived by IVF compared with non-ART children (68, 69). Some evidence has surfaced, however, regarding other epimutations that may be specifically altered. Investigators using a custom-designed Illumina array platform covering 1,536 CpG sites from 736 genes found increased hypomethylation in the placenta (63% of the 246 CpGs that differed) and greater methylation in cord blood (77% of the 358 CpGs that differed) (70). Of the specific genes affected, *CEBPA*, which affects adipogenesis and regulates glucose and lipid metabolism (71), was differentially methylated in both cord blood and placental tissue in the ART group (70).

Treatment Differences

Assisted reproductive technologies comprise multiple heterogeneous procedures, which may include ovarian stimulation for oocyte retrieval, sperm injection, in vitro culture, and cryopreservation, among others. The literature to date has rarely evaluated cardiometabolic health among children according to these finer treatment exposures. Therefore, it is unknown whether each of these processes is associated with long-term health outcomes in children conceived by ART, but the evidence thus far is briefly considered below.

The health of children conceived by ovarian stimulation apart from ART has only recently begun to be investigated (72–75), given the lack of registries or other sampling frameworks in which to identify couples and their children. Low birth weight (74, 76, 77), preterm birth (74, 76, 77), and small for gestational age (78) have been found to be increased among births conceived using clomiphene citrate or injectable gonadotropin compared with births conceived without assistance. A recent study found that 3–10-year-old boys ($n = 39$) conceived by ovulation stimulation (by different regimens of clomiphene, FSH, or both) were on average 3 cm shorter than children conceived without assistance (75). In the study reviewed above (Table 1), Scherrer et al. (50) measured FMD in children conceived after ovulation stimulation and found no significant differences in comparison with the non-ART group, although the sample sizes were small ($n = 16$ and 53, respectively).

The associations between different brands of culture media and birth outcomes have also recently been examined, with mixed findings (79–81). Two retrospective observational studies found no differences in birth weight or gestational age by the different brands of media examined, although their use corresponded to the time periods in which their clinics used a particular brand of culture (79, 81). A study randomly allocating two types of media found one (Cook media) to be associated with lower birth weight among singletons (–112 g,

$P=.03$) than another type (Vitrolife), without a difference in mean gestational age (80). No studies have investigated long-term cardiometabolic outcomes among ART children conceived by different culture media.

Intracytoplasmic sperm injection may also have differential effects than in vitro culture alone, including the human selection of sperm with chromosomal abnormalities, physical damage, and point mutations due to chemical or environmental exposure (82). The studies reviewed above (19, 22, 26) do not suggest, however, that children conceived by ICSI differ in anthropometry from children conceived by IVF alone. The largest of these studies combined five European cohorts to compare 540 ICSI- and 437 IVF-conceived children, finding the same mean height (111 cm) and similar weight (ICSI with -0.2 kg) and head circumference (ICSI with -0.2 cm) (22).

The effects of cryopreservation are also important to consider, with evidence that frozen embryo transfers resulting in live births fare better (i.e., higher birth weight, longer gestational age) (83, 84). This association may be due to survival bias, whereby less hardy embryos do not result in live birth, or to the fact that women with embryos available for cryopreservation have higher-quality embryos. To our knowledge only one study has investigated postnatal growth of 255 children born after cryopreservation, finding no differences in growth at up to 18 months of observation when compared with children conceived by fresh IVF transfers or spontaneously (35).

Fetal Growth

Impaired fetal growth has been found to be associated with markers of endothelial dysfunction in early childhood (85). In adults, FMD (a marker for endothelial dysfunction [86]) is associated with birth weight (87). Deficiencies in fetal growth could lead to impaired vascular (including endothelial function and vascular responsiveness) and kidney development (which could alter blood pressure regulation through the renin–angiotensin system). Reduction in nephron number of the kidney is associated with elevated blood pressure (88). Even though kidney development occurs late in gestation, low protein exposure during the period of oocyte maturation in one study led to reduced nephron numbers, which may be a compensatory response or downstream effect of adverse programming induced much earlier in development, possibly to protect fetal growth (89). Catch-up growth later in life serves as an indicator of fetal growth restriction. Ceelen et al. (38) showed that infant growth acceleration may be one putative cause of later CVD risk, with accelerated growth being associated with the increased blood pressure found in the ART children. Belva et al. (59) also explored whether rapid weight gain in early and late infancy was associated with blood pressure differences of ICSI-conceived adolescents at age 14 years but found no associations. No studies, however, have quantified the direct and indirect effect of fetal growth on associations, which may be better than restricting recruitment to only term children, matching on gestational age, or adding birth outcomes to statistical models because these methods can introduce bias by conditioning on a known intermediate (90).

Placental Development

The placenta acts as the crucial intersection connecting maternal nutrient supply to the fetus, playing a crucial role in cardiometabolic health (91). Placental dysfunction therefore could be an indicator of later CVD risk through leading to abnormal fetal growth, or through other pathways (92). In the non-ART population, placental weight alone has been inconsistently found to be associated with CVD and hypertension, perhaps owing to nonuniform measurement techniques (91). Recently, placental thinness independent of placental weight and birth weight was associated with later sudden cardiac death in the Helsinki study,

suggesting a possible indicator of autonomic nervous system programming (92). Placenta to birth weight ratio has been found to be increased among ART births, similar to births affected by pre-eclampsia (93). Ovarian stimulation leading to decreased endometrial receptivity could cause the placenta to compensate with abnormal growth. However, the role of the placenta as a mediator remains a data gap because no studies have investigated placental characteristics in connection with long-term cardiometabolic health in the ART population.

FUTURE STUDIES

As highlighted above, data gaps remain for determining whether growth and cardiometabolic risk differs in children conceived by ART compared with non-ART children. To account for confounding by inherited factors, some investigators have suggested that a cohort of siblings will be the ideal comparison group (94). Recent studies investigating other developmental origins of health and disease hypotheses, including gestational weight gain and diabetes exposure in utero, on future risk of obesity in the offspring have performed such sibling comparisons through the use of registry data (95, 96). Similar ART and non-ART sibling comparisons may be possible using registry data but would ideally need to have data on ovulation stimulation exposure apart from ART. However, comparison of siblings is not without limitations, including the fact that discordant siblings could be indicators of a wide range of factors, including change in partner (non-genetically identical sibs) and older parental age. Sibling cohorts will also be unable to provide more information regarding twins because few parents would have two sets of twins/multiples conceived by different methods. A sibling cohort may require recruitment over longer spans of time, because it is unlikely that there will be enough siblings born in any close period of time to evaluate small effects.

Longer periods of recruitment can generate associations due to secular differences occurring during the period, as discussed above for the study by Ceelen et al., (25, 38, 47) which recruited children as early as 1980. Assisted reproductive techniques have evolved much, as demonstrated in climbing live birth rates, especially with frozen transfers (97). It may be that the differences in children's health found by Ceelen et al. may not occur in more recent cohorts. On the other hand, does this mean that a new IVF cohort is needed in every decade to be representative? Perhaps the answer depends on the technological advancements that remain to be made and the research question at hand, with continuous recruitment also being a possibility.

In conclusion, many studies in non-ART populations have shown that cardiometabolic risk can be “programmed” in utero, manifesting as later glucose intolerance or CVD. The high rates of low birth weight and preterm birth are indicators that the ART population may be especially vulnerable to this “programming” effect. Apart from fetal growth deficits, some evidence of independent associations of vascular function has serviced. The cardiometabolic health of children conceived by ART requires further study, not only to replicate previous findings in more recent cohorts but also to tease apart the mechanisms that may be at play.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

E.H.Y. was supported by the Intramural Research Program of the *Eunice Kennedy Shriver* National Institute of Child Health & Human Development, National Institutes of Health.

REFERENCES

1. Sunderam S, Kissin DM, Flowers L, Anderson JE, Folger SG, Jamieson DJ, et al. Assisted reproductive technology surveillance—United States, 2009. *MMWR Surveill Summ.* 2012; 61:1–23. [PubMed: 23114281]
2. Sunderam S, Chang J, Flowers L, Kulkarni A, Sentelle G, Jeng G, et al. Assisted reproductive technology surveillance—United States, 2006. *MMWR Surveill Summ.* 2009; 58:1–25. [PubMed: 19521336]
3. Barker DJ. Sir Richard Doll Lecture. Developmental origins of chronic disease. *Public Health.* 2012; 126:185–9. [PubMed: 22325676]
4. McDonald SD, Han Z, Mulla S, Murphy KE, Beyene J, Ohlsson A. Preterm birth and low birth weight among in vitro fertilization singletons: a systematic review and meta-analyses. *Eur J Obstet Gynecol Reprod Biol.* 2009; 146:138–48. [PubMed: 19577836]
5. McDonald SD, Han Z, Mulla S, Ohlsson A, Beyene J, Murphy KE. Preterm birth and low birth weight among in vitro fertilization twins: a systematic review and meta-analyses. *Eur J Obstet Gynecol Reprod Biol.* 2010; 148:105–13. [PubMed: 19833428]
6. Jackson RA, Gibson KA, Wu YW, Croughan MS. Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis. *Obstet Gynecol.* 2004; 103:551–63. [PubMed: 14990421]
7. Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. *Lancet.* 1989; 2:577–80. [PubMed: 2570282]
8. Barker DJ. Fetal origins of coronary heart disease. *BMJ.* 1995; 311:171–4. [PubMed: 7613432]
9. Forsen T, Eriksson J, Tuomilehto J, Reunanen A, Osmond C, Barker D. The fetal and childhood growth of persons who develop type 2 diabetes. *Ann Intern Med.* 2000; 133:176–82. [PubMed: 10906831]
10. Ludwig AK, Sutcliffe AG, Diedrich K, Ludwig M. Post-neonatal health and development of children born after assisted reproduction: a systematic review of controlled studies. *Eur J Obstet Gynecol Reprod Biol.* 2006; 127:3–25. [PubMed: 16621225]
11. Savage T, Peek J, Hofman PL, Cutfield WS. Childhood outcomes of assisted reproductive technology. *Hum Reprod.* 2011; 26:2392–400. [PubMed: 21724570]
12. Wilson CL, Fisher JR, Hammarberg K, Amor DJ, Halliday JL. Looking downstream: a review of the literature on physical and psychosocial health outcomes in adolescents and young adults who were conceived by ART. *Hum Reprod.* 2011; 26:1209–19. [PubMed: 21362683]
13. Chen M, Norman RJ, Heilbronn LK. Does in vitro fertilisation increase type 2 diabetes and cardiovascular risk? *Curr Diabetes Rev.* 2011; 7:426–32. [PubMed: 22091747]
14. Kermani R, Zoljalai S, Kouhpayezadeh J, Nateghi M, Shahzadehfazeli A, Nedaiyard L. Evaluation of the growth process of infants conceived by assisted reproductive techniques at Royan Institute from birth to 9 months. *Iranian J Pediatr.* 2011; 21:449–54.
15. Olivennes F, Kerbrat V, Rufat P, Blanchet V, Fanchin R, Frydman R. Follow-up of a cohort of 422 children aged 6 to 13 years conceived by in vitro fertilization. *Fertil Steril.* 1997; 67:284–9. [PubMed: 9022604]
16. Pruksananonda C. Growth and development of children conceived by intracytoplasmic sperm injection at King Chulalongkorn Memorial Hospital. *J Med Assoc Thai.* 2001; 84(Suppl 1):S76–85. [PubMed: 11529384]
17. Beydoun HA, Sicignano N, Beydoun MA, Matson DO, Bocca S, Stadtmauer L, et al. A cross-sectional evaluation of the first cohort of young adults conceived by in vitro fertilization in the United States. *Fertil Steril.* 2010; 94:2043–9. [PubMed: 20159654]
18. Beydoun HA, Sicignano N, Beydoun MA, Bocca S, Stadtmauer L, Oehninger S. Pubertal development of the first cohort of young adults conceived by in vitro fertilization in the United States. *Fertil Steril.* 2011; 95:528–33. [PubMed: 20547390]
19. Basatemur E, Shevlin M, Sutcliffe A. Growth of children conceived by IVF and ICSI up to 12 years of age. *Reprod Biomed Online.* 2010; 20:144–9. [PubMed: 20159000]
20. Belva F, Henriët S, Liebaers I, Van Steirteghem A, Celestin-Westreich S, Bonduelle M. Medical outcome of 8-year-old singleton ICSI children (born ≥ 32 weeks' gestation) and a spontaneously conceived comparison group. *Hum Reprod.* 2007; 22:506–15. [PubMed: 16982659]

21. Belva F, Painter R, Bonduelle M, Roelants M, Devroey P, De Schepper J. Are ICSI adolescents at risk for increased adiposity? *Hum Reprod.* 2012; 27:257–64. [PubMed: 22081314]
22. Bonduelle M, Wennerholm UB, Loft A, Tarlatzis BC, Peters C, Henriot S, et al. A multi-centre cohort study of the physical health of 5-year-old children conceived after intracytoplasmic sperm injection, in vitro fertilization and natural conception. *Hum Reprod.* 2005; 20:413–9. [PubMed: 15576393]
23. Bowen JR, Gibson FL, Leslie GI, Saunders DM. Medical and developmental outcome at 1 year for children conceived by intracytoplasmic sperm injection. *Lancet.* 1998; 351:1529–34. [PubMed: 10326534]
24. Brandes JM, Scher A, Itzkovits J, Thaler I, Sarid M, Gershoni-Baruch R. Growth and development of children conceived by in vitro fertilization. *Pediatrics.* 1992; 90:424–9. [PubMed: 1518701]
25. Ceelen M, van Weissenbruch MM, Roos JC, Vermeiden JP, van Leeuwen FE, Delemarre-van de Waal HA. Body composition in children and adolescents born after in vitro fertilization or spontaneous conception. *J Clin Endocrinol Metab.* 2007; 92:3417–23. [PubMed: 17595253]
26. Kai CM, Main KM, Andersen AN, Loft A, Chellakooty M, Skakkebaek NE, et al. Serum insulin-like growth factor-I (IGF-I) and growth in children born after assisted reproduction. *J Clin Endocrinol Metab.* 2006; 91:4352–60. [PubMed: 16912121]
27. Koivurova S, Hartikainen AL, Sovio U, Gissler M, Hemminki E, Jarvelin MR. Growth, psychomotor development and morbidity up to 3 years of age in children born after IVF. *Hum Reprod.* 2003; 18:2328–36. [PubMed: 14585883]
28. Lee SH, Lee MY, Chiang TL, Lee MS, Lee MC. Child growth from birth to 18 months old born after assisted reproductive technology—results of a - national birth cohort study. *Int J Nurs Stud.* 2010; 47:1159–66. [PubMed: 20219195]
29. Ludwig AK, Katalinic A, Thyen U, Sutcliffe AG, Diedrich K, Ludwig M. Physical health at 5.5 years of age of term-born singletons after intracytoplasmic sperm injection: results of a prospective, controlled, single-blinded study. *Fertil Steril.* 2009; 91:115–24. [PubMed: 18206144]
30. Makhoul IR, Tamir A, Bader D, Rotschild A, Weintraub Z, Yurman S, et al. In vitro fertilisation and use of ovulation enhancers may both influence childhood height in very low birthweight infants. *Arch Dis Child Fetal Neonatal Ed.* 2009; 94:F355–9. [PubMed: 19700399]
31. Miles HL, Hofman PL, Peek J, Harris M, Wilson D, Robinson EM, et al. In vitro fertilization improves childhood growth and metabolism. *J Clin Endocrinol Metab.* 2007; 92:3441–5. [PubMed: 17566097]
32. Place I, Englert Y. A prospective longitudinal study of the physical, psychomotor, and intellectual development of singleton children up to 5 years who were conceived by intracytoplasmic sperm injection compared with children conceived spontaneously and by in vitro fertilization. *Fertil Steril.* 2003; 80:1388–97. [PubMed: 14667874]
33. Ron-El R, Lahat E, Golan A, Lerman M, Bukovsky I, Herman A. Development of children born after ovarian superovulation induced by long-acting gonadotropin-releasing hormone agonist and menotropins, and by in vitro fertilization. *J Pediatr.* 1994; 125:734–7. [PubMed: 7525915]
34. Saunders K, Spensley J, Munro J, Halasz G. Growth and physical outcome of children conceived by in vitro fertilization. *Pediatrics.* 1996; 97:688–92. [PubMed: 8628608]
35. Wennerholm UB, Bertsson-Wikland K, Bergh C, Hamberger L, Niklasson A, Nilsson L, et al. Postnatal growth and health in children born after cryopreservation as embryos. *Lancet.* 1998; 351:1085–90. [PubMed: 9660577]
36. Baker VL, Jones CE, Cometti B, Hoehler F, Salle B, Urbancsek J, et al. Factors affecting success rates in two concurrent clinical IVF trials: an examination of potential explanations for the difference in pregnancy rates between the United States and Europe. *Fertil Steril.* 2010; 94:1287–91. [PubMed: 19815197]
37. Carlin JB, Gurrin LC, Sterne JA, Morley R, Dwyer T. Regression models for twin studies: a critical review. *Int J Epidemiol.* 2005; 34:1089–99. [PubMed: 16087687]
38. Ceelen M, van Weissenbruch MM, Prein J, Smit JJ, Vermeiden JP, Spreeuwenberg M, et al. Growth during infancy and early childhood in relation to blood pressure and body fat measures at age 8–18 years of IVF children and spontaneously conceived controls born to subfertile parents. *Hum Reprod.* 2009; 24:2788–95. [PubMed: 19648588]

39. Buck Louis GM, Schisterman EF, Dukic VM, Schieve LA. Research hurdles complicating the analysis of infertility treatment and child health. *Hum Reprod.* 2005; 20:12–8. [PubMed: 15489239]
40. Raatikainen K, Kuivasaari-Pirinen P, Hippelainen M, Heinonen S. Comparison of the pregnancy outcomes of subfertile women after infertility treatment and in naturally conceived pregnancies. *Hum Reprod.* 2012; 27:1162–9. [PubMed: 22333986]
41. Yang W, Kelly T, He J. Genetic epidemiology of obesity. *Epidemiol Rev.* 2007; 29:49–61. [PubMed: 17566051]
42. Shah DK, Missmer SA, Berry KF, Racowsky C, Ginsburg ES. Effect of obesity on oocyte and embryo quality in women undergoing in vitro fertilization. *Obstet Gynecol.* 2011; 118:63–70. [PubMed: 21691164]
43. Shayeb AG, Harrild K, Mathers E, Bhattacharya S. An exploration of the association between male body mass index and semen quality. *Reprod Biomed Online.* 2011; 23:717–23. [PubMed: 22019618]
44. Linne Y. Effects of obesity on women's reproduction and complications during pregnancy. *Obes Rev.* 2004; 5:137–43. [PubMed: 15245382]
45. Bhargava SK, Sachdev HS, Fall CH, Osmond C, Lakshmy R, Barker DJ, et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. *N Engl J Med.* 2004; 350:865–75. [PubMed: 14985484]
46. Monteiro PO, Victora CG. Rapid growth in infancy and childhood and obesity in later life—a systematic review. *Obes Rev.* 2005; 6:143–54. [PubMed: 15836465]
47. Ceelen M, van Weissenbruch MM, Vermeiden JP, van Leeuwen FE, Delemarre-van de Waal HA. Growth and development of children born after in vitro fertilization. *Fertil Steril.* 2008; 90:1662–73. [PubMed: 18163998]
48. Ceelen M, van Weissenbruch MM, Vermeiden JP, van Leeuwen FE, Delemarre-van de Waal HA. Cardiometabolic differences in children born after in vitro fertilization: follow-up study. *J Clin Endocrinol Metab.* 2008; 93:1682–8. [PubMed: 18285409]
49. Sakka SD, Loutradis D, Kanaka-Gantenbein C, Margeli A, Papastamataki M, Papassotiiriou I, et al. Absence of insulin resistance and low-grade inflammation despite early metabolic syndrome manifestations in children born after in vitro fertilization. *Fertil Steril.* 2010; 94:1693–9. [PubMed: 20045517]
50. Scherrer U, Rimoldi SF, Rexhaj E, Stuber T, Duplain H, Garcin S, et al. Systemic and pulmonary vascular dysfunction in children conceived by assisted reproductive technologies. *Circulation.* 2012; 125:1890–6. [PubMed: 22434595]
51. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics.* 2011; 128(Suppl 5):S213–6. [PubMed: 22084329]
52. Muntner P, He J, Cutler JA, Wildman RP, Whelton PK. Trends in blood pressure among children and adolescents. *JAMA.* 2004; 291:2107–13. [PubMed: 15126439]
53. Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. *Am J Hypertens.* 1995; 8:657–65. [PubMed: 7546488]
54. Srinivasan SR, Myers L, Berenson GS. Changes in metabolic syndrome variables since childhood in prehypertensive and hypertensive subjects: the Bogalusa Heart Study. *Hypertension.* 2006; 48:33–9. [PubMed: 16769996]
55. Franks PW, Hanson RL, Knowler WC, Sievers ML, Bennett PH, Looker HC. Childhood obesity, other cardiovascular risk factors, and premature death. *N Engl J Med.* 2010; 362:485–93. [PubMed: 20147714]
56. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. *JAMA.* 2002; 288:1882–8. [PubMed: 12377087]
57. Celemajer DS. Manipulating nature: might there be a cardiovascular price to pay for the miracle of assisted conception? *Circulation.* 2012; 125:1832–4. [PubMed: 22434594]

58. Watkins AJ, Platt D, Papenbrock T, Wilkins A, Eckert JJ, Kwong WY, et al. Mouse embryo culture induces changes in postnatal phenotype including raised systolic blood pressure. *Proc Natl Acad Sci U S A*. 2007; 104:5449–54. [PubMed: 17372207]
59. Belva F, Roelants M, De Schepper J, Roseboom TJ, Bonduelle M, Devroey P, et al. Blood pressure in ICSI-conceived adolescents. *Hum Reprod*. 2012; 27:3100–8. [PubMed: 22814483]
60. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. *Circulation*. 1997; 96:1432–7. [PubMed: 9315528]
61. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. *Circulation*. 2007; 115:459–67. [PubMed: 17242284]
62. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. *Circulation*. 2010; 121:505–11. [PubMed: 20083680]
63. Chason RJ, Csokmay J, Segars JH, DeCherney AH, Armant DR. Environmental and epigenetic effects upon preimplantation embryo metabolism and development. *Trends Endocrinol Metab*. 2011; 22:412–20. [PubMed: 21741268]
64. Amor DJ, Halliday J. A review of known imprinting syndromes and their association with assisted reproduction technologies. *Hum Reprod*. 2008; 23:2826–34. [PubMed: 18703582]
65. Eroglu A, Layman LC. Role of ART in imprinting disorders. *Semin Reprod Med*. 2012; 30:92–104. [PubMed: 22549709]
66. Lidegaard O, Pinborg A, Andersen AN. Imprinting diseases and IVF: Danish National IVF cohort study. *Hum Reprod*. 2005; 20:950–4. [PubMed: 15665017]
67. Cohen MM Jr. Beckwith-Wiedemann syndrome: historical, clinicopathological, and etiopathogenetic perspectives. *Pediatr Dev Pathol*. 2005; 8:287–304. [PubMed: 16010495]
68. Oliver VF, Miles HL, Cutfield WS, Hofman PL, Ludgate JL, Morison IM. Defects in imprinting and genome-wide DNA methylation are not common in the in vitro fertilization population. *Fertil Steril*. 2012; 97:147–53. [PubMed: 22112648]
69. Rancourt RC, Harris HR, Michels KB. Methylation levels at imprinting control regions are not altered with ovulation induction or in vitro fertilization in a birth cohort. *Hum Reprod*. 2012; 27:2208–16. [PubMed: 22587996]
70. Katari S, Turan N, Bibikova M, Erinle O, Chalian R, Foster M, et al. DNA methylation and gene expression differences in children conceived in vitro or in vivo. *Hum Mol Genet*. 2009; 18:3769–78. [PubMed: 19605411]
71. Olofsson LE, Orho-Melander M, William-Olsson L, Sjöholm K, Sjöström L, Groop L, et al. CCAAT/enhancer binding protein alpha (C/EBPalpha) in adipose tissue regulates genes in lipid and glucose metabolism and a genetic variation in C/EBPalpha is associated with serum levels of triglycerides. *J Clin Endocrinol Metab*. 2008; 93:4880–6. [PubMed: 18765514]
72. Carson C, Kelly Y, Kurinczuk JJ, Sacker A, Redshaw M, Quigley MA. Effect of pregnancy planning and fertility treatment on cognitive outcomes in children at ages 3 and 5: longitudinal cohort study. *BMJ*. 2011; 343:d4473. [PubMed: 21791498]
73. Brinton LA, Kruger KS, Thomsen BL, Sharif HF, Graubard BI, Olsen JH, et al. Childhood tumor risk after treatment with ovulation-stimulating drugs. *Fertil Steril*. 2004; 81:1083–91. [PubMed: 15066468]
74. Klemetti R, Sevón T, Gissler M, Hemminki E. Health of children born after ovulation induction. *Fertil Steril*. 2010; 93:1157–68. [PubMed: 19171331]
75. Savage T, Peek JC, Robinson EM, Green MP, Miles HL, Mouat F, et al. Ovarian stimulation leads to shorter stature in childhood. *Hum Reprod*. 2012; 27:3092–9. [PubMed: 22777529]
76. Ombelet W, Martens G, De Schepper P, Gerris J, Bosmans E, Ruysinck G, et al. Perinatal outcome of 12,021 singleton and 3108 twin births after non-IVF-assisted reproduction: a cohort study. *Hum Reprod*. 2006; 21:1025–32. [PubMed: 16339165]
77. Kallen B, Olausson PO, Nygren KG. Neonatal outcome in pregnancies from ovarian stimulation. *Obstet Gynecol*. 2002; 100:414–9. [PubMed: 12220758]

78. D'Angelo DV, Whitehead N, Helms K, Barfield W, Ahluwalia IB. Birth outcomes of intended pregnancies among women who used assisted reproductive technology, ovulation stimulation, or no treatment. *Fertil Steril.* 2011; 96:314–20. [PubMed: 21718990]
79. Eaton JL, Lieberman ES, Stearns C, Chinchilla M, Racowsky C. Embryo culture media and neonatal birthweight following IVF. *Hum Reprod.* 2012; 27:375–9. [PubMed: 22128298]
80. Nelissen EC, van Montfoort AP, Coonen E, Derhaag JG, Geraedts JP, Smits LJ, et al. Further evidence that culture media affect perinatal outcome: findings after transfer of fresh and cryopreserved embryos. *Hum Reprod.* 2012; 27:1966–76. [PubMed: 22552689]
81. Vergouw CG, Hanna KE, Doejaaren E, Hompes PG, Lambalk CB, Schats R. The influence of the type of embryo culture medium on neonatal birth-weight after single embryo transfer in IVF. *Hum Reprod.* 2012; 27:2619–26. [PubMed: 22791752]
82. Simpson JL, Lamb DJ. Genetic effects of intracytoplasmic sperm injection. *Semin Reprod Med.* 2001; 19:239–49. [PubMed: 11679905]
83. Kalra SK, Ratcliffe SJ, Coutifaris C, Molinaro T, Barnhart KT. Ovarian stimulation and low birth weight in newborns conceived through in vitro fertilization. *Obstet Gynecol.* 2011; 118:863–71. [PubMed: 21934450]
84. Wennerholm UB, Soderstrom-Anttila V, Bergh C, Aittomaki K, Hazekamp J, Nygren KG, et al. Children born after cryopreservation of embryos or oocytes: a systematic review of outcome data. *Hum Reprod.* 2009; 24:2158–72. [PubMed: 19458318]
85. Skilton MR, Evans N, Griffiths KA, Harmer JA, Celermajer DS. Aortic wall thickness in newborns with intrauterine growth restriction. *Lancet.* 2005; 365:1484–6. [PubMed: 15850633]
86. Kelm M. Flow-mediated dilatation in human circulation: diagnostic and therapeutic aspects. *Am J Physiol Heart Circ Physiol.* 2002; 282:H1–5. [PubMed: 11748041]
87. Leeson CP, Whincup PH, Cook DG, Donald AE, Papacosta O, Lucas A, et al. Flow-mediated dilation in 9- to 11-year-old children: the influence of intrauterine and childhood factors. *Circulation.* 1997; 96:2233–8. [PubMed: 9337195]
88. Barker DJ, Bagby SP, Hanson MA. Mechanisms of disease: in utero programming in the pathogenesis of hypertension. *Nat Clin Pract Nephrol.* 2006; 2:700–7. [PubMed: 17124527]
89. Watkins AJ, Fleming TP. Blastocyst environment and its influence on off-spring cardiovascular health: the heart of the matter. *J Anat.* 2009; 215:52–9. [PubMed: 19215321]
90. VanderWeele TJ, Mumford SL, Schisterman EF. Conditioning on intermediates in perinatal epidemiology. *Epidemiology.* 2012; 23:1–9. [PubMed: 22157298]
91. Lewis R, Poore K, Godfrey K. The role of the placenta in the developmental origins of health and disease—implications for practice. *Rev Gynaecol Perinat Pract.* 2006; 6:70–9.
92. Barker DJ, Larsen G, Osmond C, Thornburg KL, Kajantie E, Eriksson JG. The placental origins of sudden cardiac death. *Int J Epidemiol.* 2012; 41:1394–9. [PubMed: 22997261]
93. Haavaldsen C, Tanbo T, Eskild A. Placental weight in singleton pregnancies with and without assisted reproductive technology: a population study of 536,567 pregnancies. *Hum Reprod.* 2012; 27:576–82. [PubMed: 22184202]
94. Nejat EJ, Buyuk E. Reproductive technologies and the risk of birth defects. *N Engl J Med.* 2012; 367:875–6. [PubMed: 22931336]
95. Lawlor DA, Lichtenstein P, Langstrom N. Association of maternal diabetes mellitus in pregnancy with offspring adiposity into early adulthood: sibling study in a prospective cohort of 280,866 men from 248,293 families. *Circulation.* 2011; 123:258–65. [PubMed: 21220735]
96. Lawlor DA, Lichtenstein P, Fraser A, Langstrom N. Does maternal weight gain in pregnancy have long-term effects on offspring adiposity? A sibling study in a prospective cohort of 146,894 men from 136,050 families. *Am J Clin Nutr.* 2011; 94:142–8. [PubMed: 21562086]
97. Centers for Disease Control and Prevention. American Society for Reproductive Medicine. Society for Assisted Reproductive Technology. 2009 Assisted reproductive technology success rates: national summary and fertility clinic reports. US Department of Health and Human Services; Atlanta, GA: 2011.
98. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics.* 2004; 114:555–76. [PubMed: 15286277]

TABLE 1

CVD risk factors among children conceived by ART.

First author, year (reference)	Population	N	Age(s)	BMI (kg/m ²)	SBP (mm Hg)	DBP (mm Hg)	IVF/ICSI vs. non-ART					
							HDL (mmol/L)	LDL (mmol/L)	TC (mmol/L)	TG (mmol/L)	FPG (mmol/L)	
Ceelen, 2007 (48)	The Netherlands, from one site of the OMEGA study (1980–1994)	225 IVF and 225 non-ART singletons born from women with subfertility	8–18 y (mean 12 y)	19.1 vs. 18.7	109 vs. 105 ^a	61 vs. 59 ^a	n/a	n/a	n/a	n/a	n/a	5.0 vs. 4.8 ^a
Belva, 2007 (20)	Belgium, fertility clinic and schools in the area	150 ICSI (32 wk), 147 non-ART singletons	8y	16.2 vs. 16.3	100 vs. 95 ^a	60 vs. 50 ^a	n/a	n/a	n/a	n/a	n/a	n/a
Belva, 2012 (59) ^b	Belgium, fertility clinic and schools in the area	217 ICSI (32 wk), 223 non-ART singletons	14y	B: 19.1 vs. 19.2 G: 19.7 vs. 19.3	B: 113 vs. 116 G: 109 vs. 111	B: 64 vs. 65 G: 64 vs. 66	n/a	n/a	n/a	n/a	n/a	n/a
Miles, 2007 (31)	New Zealand, IV and peers (or 6 siblings)	69 IVF (34 ICSI) and 71 non-ART term singletons	4–10 y (mean 6 y)	15.68 vs. 16.47 ^a	n/a	n/a	1.67 vs. 1.53 ^a	2.37 vs. 2.42	4.33 vs. 4.31	0.65 vs. 0.78 ^a	4.7 vs. 4.8	
Sakka, 2010 (49)	Athens, fertility department vs. general hospital	106 IVF age-matched non-treated	4–14 y	BMI z score: 0.1 vs. 0	SDS: 03 vs. 0.3	SDS: 0.7 vs. 0.2 ^a	1.38 vs. 1.41	2.61 vs. 2.63	4.29 vs. 4.32	0.67 vs. 0.59 ^a	4.64 vs. 4.64	
Scherret, 2012 (50)	Switzerland, IVF and peers (or 5 siblings)	65 IVF (44 ICSI) and 57 non-ART term singletons	Mean 11 y (non-ART older by 1 y)	17.9 vs. 18.8	113 (both)	71 (both)	1.55 vs. 1.48	2.73 vs. 2.90	4.57 vs. 4.62	0.73 vs. 0.75	4.54 vs. 4.73	

Note: Non-ART = conception without use of infertility treatment of any kind; HDL = high-density lipoprotein; LDL = low-density lipoprotein; TC = total cholesterol; TG = triglycerides; FPG = fasting plasma glucose; n/a = not applicable; SDS = standard deviation score derived by Sakka et al. according to a national reference (98).

Yeung. Cardiometabolic health of ART kids. Fertil Steril 2013.

^aSignificant at $P < .05$ comparing IVF vs. controls.

^bBelva, 2012 stratified by gender (B = boys; G = girls).